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Abstract: An effective treatment for the advanced stages of chronic obstructive
pulmonary disease (COPO) has not been established yet. We report our recent
experience of one patient with pUlmonary emphysema treated by dietary supplementa-
tion of n-3 fatty acid for two months. He presented improvements in clinical symptoms
and pulmonary function, and suppression of leukotriene 8 4 generation by peripheral
leukocytes. We consequently suppose that dietary treatment with n-3 fatty acids (perilla
seed oil) may offer benefits for the treatment of pulmonary emphysema by competitively
inhiabiting the conversion of arachidonicacid to leukotrienes and prostanoids.
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Introduction
An effective treatment for the advanced stages of
chronic obstructive pulmonary disease (COPD) has
not been established yet. Several modalities for COPD
treatment such as medical treatment (I), pulmonary
rehabilitation (2,3) and surgical treatment (4) have
been employed, but these are merely symptomatic
therapy, inefficient, and frequently limited by the side
effects of medication and the risk of surgical treatment
(5-7).
In this study, we reported our recent experience of
one patient with pulmonary emphysema, who received
dietary treatment with supplementation of n-3 fatty
acid for two months, and presented improvements in
clinical symptoms, pulmonary function and suppress-
ion of leukotriene B4 (LTB4) generation by peripheral
leukocytes.
Case Report
A 67-year-old man (height 157 cm, weight 42 kg)
with COPD was admitted to our hospital for the first
time in September 1995. He was a previous smoker
with smoking history of 69 pack-years. He had
experienced wheezing and slight dyspnea on exertion
since he was 65 years old, and consulted doctor
because his symptoms were gradually worsening
(Hugh-Jones IV). He was diagnosed with pulmonary
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Table 2. Pulmonary function tests on first admission
Pulmonary function tests showed severe reduction
in PVC (2.32L, n.8%pred), FEY I (O.82L), FEY I
IFYC (37.6%) and \125 (0.19L, 13.4%pred), suggest-
ing severe airflow obstruction especially in the pe-
ripheral airway (Table 2). Blood gas analysis revealed
hypoxemia (Table I).
After admission, the patient underwent complex spa
therapy (swimming training in hot spring pool, inhala-
tion of iodine salt solution, fango therapy)(8) with
glucocorticoid inhalation (200 flg /day of beclo-
methasone dipropionate) and bronchodialators for two
months. No apparent improvement was found in
pulmonary function (Table 2), including the peak
expiratory flow (PEF)(l90-230Umin) in the early
morning despite gradual improvement of dyspnea
(Hugh-Jones III). After discharge from our hospital, he
was monitored by his home doctor for eight months.
In August 1996, the patient was admitted to our
hospital a second time, due to gradual aggravation of
exertional dyspnea (Hugh-Jones IY). Again, the find-
ings of blood chemistry and urinalysis were normal,
pulmonary function tests revealed severe airflow ob-
struction, especially in the peripheral small airway,
and blood gas analysis showed hypoxemia (Table 3).
The values of FEY I and PEF improved, but did not
exceed 15% fluctuation, after inhalation of a (3-
MMF : maximal midexpiratory flow
PEFR : peak expiratory flow rate
PEF : peak expiratory flow
HT: height
emphysema and treated unsuccessfully with broncho-
dilators and expectorants.
At the time of the first admission, a physical
examination revealed a decrease in breath sound over
both lung fields on auscultation. The findings of blood
chemistry and urinalysis were normal. The serum IgE
level was 139.4 IU/ml and no specific antibodies for
inhaled allergens were detected by the radioallergo-
sorben test (RAST)(Table I).
Table I. Laboratory data on first admission
Hematok>gy IgE(RAST) House dust (-)
WBC 7700 /mml M~e (-)
Seg 29 " Candida (-)
Stab 24 "
Lym 33 " Blood chemistry
Mo 11 " T-eHO 190 mg/dl
Eo 3 " TP 6.7 mg/dl
Ba 1 % AST 24 lUlL
RBC 545 x 10'/mm3 ALT S lUlL
Hb 16.4 g/dl ALP 74 lUlL
Het 49.5 % BUN 15.6 mg/dl
PLT 29.0 x 10"/mm3 Cr 1.0 mg/dl
Ser~ogy Arterial ~ood gas(room air)
CRP 0.' mg/dl pH 7.40
ESR 3 mmlh PO, 75.0 mmHg
IgG 1036 mg/dl PCO, 39.0 mmHg
IgA 197 mg/dl HCO, 24.7 mEq/L
IgM 60 mg/dl BE -D.2
IgE 139.4IU/ml SaOz 94.9 %
RAST: radioallergosorben test
A chest X-ray revealed a hyperlucent lung and
descent of the diaphragm (Fig. I). CT scans of the
nasal cavity and sinuses showed normal findings.
Figure I. Chest radiograph on admission showing a
hyperlucent lung and descent of the dia-
phragm.
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Table 3. Pulmonary function tests and arterial blood
gas analysis on 2nd admission
on admjssion at discharge
Pulumonary function tests
FVC l 2.24 2.58
%FVC % 71.3 82.6
FEV, l 0.88 0.97
FEV,/FVC % 39.3 37.6
MMF l/5(%) 0.36(12.1) 0.38 (13.0)
PEFR LlS(%) 2.68 (35.8) 3.18 (42.6)
050 liS (%) 0.35 (8.0) 0.38 (8.8)
V's liS (%) 0.20 (14.5) 0.20 (14.9)
Vzs/HT L/S/M 0.38 0.13
PEF LIM 190 290
%FRC 104.5
%TlC 118.5
%RV 199.4
RV/TLC % 126.9
%DLCO 68.0
DlCOIVA 1.61
Arterial blood gas(room air)
pH 7.43 7.45
POz mmHg 75.0 76.0
PCO, mmHg 33.9 34.3
HCO l ' mEq/L 23.1 23.9
8E -1.3 -0.3
Sa02 % 95.6 95.7
MMF : maximal midexpiratory flow
PEFR : peak expiratory flow rate
PEF : peak expiratory flow
HT: height
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(b) dietary supplementation with a-Linolenic acid (a
-LNA), the n-3 parent fatty acid, is beneficial to
bronchial asthma patients with regard to symptoms,
inhibiting the production of LTB4 and C4 from
arachidonic acid in leukocytes (8,13) as well as
eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA)( 14).
There are a few retrospective studies of COPD
which have focused primarily on the effects of fish oil
or EPA. With a dietary questionnaire, Sharer et al.
(d) studied the relationship between dietary intake of fi h
containing n-3 polyunsaturated fatty acids, principally
EPA acid and DHA. and COPD in smokers (15). A
high dietary intake of n-3 fatty acids was inversely
related to the risk of COPD in a quantity-dependent
Figure 2. HRCT scan showing emphysematous change
such as many low attenuation areas (LAAs) in
the lung fields (a,b). HRCT findings were also
analyzed quantitatively, defining lung areas
with CT numbers less than -950 Hounsfield
Units (HU) as LAAs. The percentages of
LAAs on HRCT were 72.6% at the top of the
aortic arch (c), and 49.3% at a level of 2 cm
above the diaphragm (d).
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3. Clinical course of the patient during the
second admission. Changes of peak ex-
piratory flow (PEF) in the early
morning ( • ) and in the evening ( • ),
and synthesis of LTB~ ( • ) by peripheral
leukocytes stimulated by Ca2+ ionophore.
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fashion, and may protect cigarette smokers against
COPD. The pathogenesis of chronic bronchitis, em-
physema and deterioration of lung function in smokers
is likely to involve inflammatory processes resulting
from an accumulation of neutrophils in the lung (16),
increased production of LTB4 by leukocytes (17), a
potent inflammatory metabolite of arachidonic acid,
and enhanced release of reactive oxygen metabolite
(e.g.superoxide anions) by alveolar macrophages (18).
Both LTB4 and reactive oxygen metabolite may
stimulate mucus secretion in the airways, and have
also been implicatied in the proteinase-antiproteinase
theory of emphysema (19).
Although the net in vivo effect of n-3 fatty acids
might be difficult to predict from in vitro studies,
some workers have reported that supplementing the
diet with n-3 fatty acids interferes with all of these
pathogenic mechanisms, because n-3 fatty acids re-
duce the chemotactic responsiveness of neutrophils
(20), inhibit the production of LTB4 from arachidonic
acid in leukocytes (21), and decrease the production of
superoxide anions in leukocytes (22,23). n-3 fatty
acids also decrease the production of other putative
mediators of pulmonary inflammation, including pla-
telet-activating factor (24), interleukin-l (25-27), and
tumor neurosis factor (25,26). n-3 fatty acids have
been also reported to influence the kinds of bacteria
(28-30) that might be able to survive in a chronic
infection, and these findings might have implications
for n-3 fatty acid enrichment of any organ with a
normal bacterial flora or where microbial host in-
teractions are involved in disease processes. It has
been reported that n-3 fatty acids can reduce blood
viscosity on red cell flexibility in animal models (31,
32), offering improvement in the pulmonary hemo-
dynamic function.
Leukotrienes (LTs) are one of the most important
chemical mediators from inflammatory cells. Peptic
leukotrienes (LTC4, D4, and E4) have a broncho-
constricting action and LTB4 is known as a strong
chemotactic factor. These LTs are generated from
arachidonic acid (AA), which is a product from
membrane phospholipids during cell activation
through the 5-lipoxygenase pathway. Sulfidopeptide
LTs of the 'five series' (LTCs and Es) from EPA have
relatively similar properties to those of the 'four
series' (LTC4, D4 and E4) from arachidonate (33). In
contrast, the generation of LTB4 which is chemotactic
and recruits many inflammatory cells to the focus of
inflammation, and both LTB4 from AA and LTBs
from EPA have similar biological activities. The
action of LTBs is, however, very weak compared with
that of LTB4• In contrast, cyclcoxygenase products
from EPA have different biological activities to those
from AA. Thromboxane A3 does not stimulate pla-
telets, in contrast to thromboxane A2• LTBs and
thromboxane A3 made from n-3 fatty acids differ in
the degree and character of their biological activities to
LTB4 and thromboxane A2 dericed from arachidonate.
The clinical course of this case with the diet therapy
using a -LNA-enriched perilla seed oil supplementa-
tion showed an apparent improvement of exertional
dyspnea and pulmonary function accompanied by a
decrease in the generation of LTB4 by leukocytes. The
findings may suggest a mechanism for dietary supp-
lementation with n-3 fatty acids for COPD. We
consequently suppose that competitively inhibiting the
conversion of arachidonic acid (AA) to leukotrienes
(LTs) and prostanoids, forming fewer active me-
tabolites such as LTBs and thromboxane A3, may be
the most important effect of dietary supplementation
with n-3 fatty acids.
Perilla seed oil supplementation seems to be benefi-
cial in the treatment of pulmonary emphysema.
Further prospective studies with more subjects are
needed to develop a diet therapy for COPD, and
further studies are needed to investigate the effects of
dietary supplementation with n-3 fatty acids.
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nl3系脂肪散を強化した食事療法が有効と考えら
れた肺気腫の一例
○柘野浩史,岡本 誠,原田誠之,芦田耕三,
光延文裕,御船尚志,保崎泰弘,谷崎勝朗,
辻 孝夫り
岡山大学医学部三朝分院内科,
1)医学部第一内科
今回我々は,肺気腫の症例に対してn-3系脂肪
酸を強化した食事療法をおこない,臨床症状,呼
吸機能検査所見ともに速やかに改善を認め,同時
に白血球のロイコトリエン84産生能が著明に減
少した一例を経験したので報告する｡
56
症例は67歳,男性｡主訴は労作時呼吸困難｡
l第一回目入院】3カ月間入院し,薬物療法,追
泉を用いた理学療法を行った｡自覚症状はやや改
善が見られたが,呼吸機能検査所見の改善は得ら
れなかった｡【第二回目入院】1年後に再入院｡
∩-3系脂肪酸強化食事療法も併用した｡自覚症状
および,呼吸機能検査上,PVC,FEV1.0,PEP
などに改善を認めた｡n-3系脂肪酸はアラキドン
酸代謝を通してロイコトリエン合成に関与すると
推定されるが,経渦中に白血球のLTB4産生能の
減少を認めた｡
この症例は肺気腫に対するn-3系脂肪酸強化食
事療法の有用性が示唆され,病態を考える上でも
興味深いと考えられた｡
